The levels of the sex hormones are not different between type 1 and type 2 endometrial cancer

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wan, Jiayi ^a   Gao, Yifei ^b   Zeng, Ke ^a   Yin, Yongxiang ^a   Zhao, Min ^a   Wei, Jia ^c   Chen, Qi ^b,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; SEX HORMONE; TUMOR PROTEIN;

ADULT; AGED; BLOOD; CLASSIFICATION; CLINICAL TRIAL; ENDOMETRIUM TUMOR; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ENDOMETRIAL NEOPLASMS; FEMALE; GONADAL STEROID HORMONES; HUMANS; MIDDLE AGED; NEOPLASM PROTEINS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 85006856448     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep39744     Document Type: Article

References (30)

1. World cancer report: Cancer Worldwide, 3rd edn, page 12-18, Eds Stewart, B. W. & Wild, C. (Lyon, France, 2014).
2. Siegel, R., Ward, E., Brawley, O. & Jemal, A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61, 212-236, doi: 10.3322/caac.20121 (2011).
3. Setiawan, V. W. et al. Age at last birth in relation to risk of endometrial cancer: pooled analysis in the epidemiology of endometrial cancer consortium. Am J Epidemiol 176, 269-278, doi: 10.1093/aje/kws129 (2012).
4. Nichols, H. B. et al. From menarche to menopause: trends among US Women born from 1912 to 1969. Am J Epidemiol 164, 1003-1011, doi: 10.1093/aje/kwj282 (2006).
5. Karageorgi, S., Hankinson, S. E., Kraft, P. & De Vivo, I. Reproductive factors and postmenopausal hormone use in relation to endometrial cancer risk in the Nurses' Health Study cohort 1976-2004. Int J Cancer 126, 208-216, doi: 10.1002/ijc.24672 (2010).
6. Kaaks, R., Lukanova, A. & Kurzer, M. S. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev 11, 1531-1543 (2002).
7. Jamison, P. M., Noone, A. M., Ries, L. A., Lee, N. C. & Edwards, B. K. Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008. Cancer Epidemiol Biomarkers Prev 22, 233-241, doi: 10.1158/1055-9965.EPI-12-0996 (2013).
8. Dossus, L. et al. Reproductive risk factors and endometrial cancer: the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 127, 442-451, doi: 10.1002/ijc.25050 (2010).
9. Grady, D., Gebretsadik, T., Kerlikowske, K., Ernster, V. & Petitti, D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85, 304-313, doi: 10.1016/0029-7844(94)00383-o (1995).
10. Williams Gynecology: Endometrial Cancer, 2nd edn, page 817-819, Eds Hoffman, B. et al., (McGraw-Hill., 2012).
11. Comprehensive Gynecology: Neoplastic Diseases of the Uterus. 6th edn, page 713-736, Eds Soliman, P. & Lu, K., (Mosby, 2013).
12. Bokhman, J. V. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15, 10-17 (1983).
13. Corpus: Epithelial Tumors, in Principles and Practice of Gynecologic Oncology. 5th Edn, page 683-689, Eds McMeekin, D. S. (Lippincott Williams, 2009).
14. Chen Q., Tong,. M., Guo, F., Lau, S. & Zhao, M. Parity Correlates with the Timing of Developing Endometrial Cancer, But Not Subtype of Endometrial Cancer Journal of Cancer 6, 1087 (2015).
15. Crosbie, E. J., Zwahlen, M., Kitchener, H. C., Egger, M. & Renehan, A. G. Body mass index, hormone replacement therapy, and endometrial cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 19, 3119-3130, doi: 10.1158/1055-9965.EPI-10-0832 (2010).
16. Setiawan, V. W. et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol 31, 2607-2618, doi: 10.1200/JCO.2012.48.2596 (2013).
17. Pike, M. C., Pearce, C. L. & Wu, A. H. Prevention of cancers of the breast, endometrium and ovary. Oncogene 23, 6379-6391, doi: 10.1038/sj.onc.1207899 (2004).
18. Srijaipracharoen, S. et al. Expression of ER, PR, and Her-2/neu in endometrial cancer: a clinicopathological study. Asian Pac J Cancer Prev 11, 215-220 (2010).
19. Kobel, M. et al. Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study. Gynecol Oncol 141, 559-563, doi: 10.1016/j.ygyno.2016.04.008 (2016).
20. Endometrial cancer: Cancer epidemiology and prevention, 3rd Edn, page 12-18, Eds Cook L. S. et al. (Oxford, 2006).
21. Kauppila, A., Janne, O., Kujansuu, E. & Vihko, R. Treatment of advanced endometrial adenocarcinoma with a combined cytotoxic therapy. Predictive value of cytosol estrogen and progestin receptor levels. Cancer 46, 2162-2167 (1980).
22. Quade, B. J. et al. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosomes Cancer 40, 97-108, doi: 10.1002/gcc.20018 (2004).
23. Enriori, C. L. & Reforzo-Membrives, J. Peripheral aromatization as a risk factor for breast and endometrial cancer in postmenopausal women: a review. Gynecol Oncol 17, 1-21 (1984).
24. Kanat-Pektas, M., Yenicesu, O., Gungor, T. & Bilge, U. Predictive power of sexual hormones and tumor markers in endometrial cancer. Arch Gynecol Obstet 281, 709-715, doi: 10.1007/s00404-009-1228-4 (2010).
25. Allen, N. E. et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 15, 485-497, doi: 10.1677/ERC-07-0064 (2008).
26. Gao, Y. et al. The prevalence of endometrial cancer in pre- and postmenopausal Chinese women. Menopause, doi: 10.1097/GME.0000000000000684 (2016).
27. Davies, S., Bax, C. M., Chatzaki, E., Chard, T. & Iles, R. K. Regulation of endometrial cancer cell growth by luteinizing hormone (LH) and follicle stimulating hormone (FSH). Br J Cancer 83, 1730-1734, doi: 10.1054/bjoc.2000.1507 (2000).
28. Risch, H. A. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90, 1774-1786 (1998).
29. Setiawan, V. W. et al. Racial/ethnic differences in endometrial cancer risk: the multiethnic cohort study. Am J Epidemiol 165, 262-270, doi: 10.1093/aje/kwk010 (2007).
30. Evans, T. et al. Differential trends in the rising incidence of endometrial cancer by type: data from a UK population-based registry from 1994 to 2006. Br J Cancer 104, 1505-1510, doi: 10.1038/bjc.2011.68 (2011).